Pharma industry
Technological strategies for building resilience and category security
While some will remember the COVID-19 pandemic as a time filled with lockdowns, difficulties, and limitations, for others, it was a period of intensive development and addressing previously unknown challenges. The second group is certainly headed by specialists from the pharmaceutical industry. The sector faced the accelerated pace of work on new vaccines and treatment systems, as well as increased political and social pressure to renounce intellectual property rights due to the pandemic.
